L-744,832

L-744,832 (also identified in bioinformatics databases as LLL-3348) is a potent, cell-permeable, and selective peptidomimetic inhibitor of protein farnesyltransferase (PFTase). Developed by Merck, it was designed to mimic the C-terminal CAAX motif of Ras proteins, thereby competitively inhibiting the enzyme responsible for farnesylation. This post-translational modification is essential for the membrane anchoring and biological activity of Ras, a protein frequently mutated in human cancers. By blocking Ras farnesylation, L-744,832 inhibits downstream signaling pathways such as MAPK and PI3K/Akt, leading to cell cycle arrest and apoptosis in various tumor models. While it reached Phase 1 clinical trials for the treatment of solid tumors and leukemias, its clinical development was largely superseded by other farnesyltransferase inhibitors. More recently, L-744,832 has been highlighted in computational drug repurposing studies for its potential to modulate inflammatory responses and gene expression signatures associated with COVID-19 and intracranial aneurysms, particularly through its predicted interaction with Interleukin-10 (IL-10) pathways.

Other names

LLL-3348LLL3348LLL 3348L-744,832L-744832L744832L 744832